Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
1(14%)
Results Posted
50%(2 trials)

Phase Distribution

Ph phase_1
3
43%
Ph phase_2
3
43%
Ph not_applicable
1
14%

Phase Distribution

3

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
3(42.9%)
Phase 2Efficacy & side effects
3(42.9%)
N/ANon-phased studies
1(14.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

7

all time

Status Distribution
Active(1)
Completed(4)
Other(2)

Detailed Status

Completed4
unknown2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
1
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 13 (42.9%)
Phase 23 (42.9%)
N/A1 (14.3%)

Trials by Status

completed457%
unknown229%
recruiting114%

Recent Activity

1 active trials
Showing 5 of 7
recruitingnot_applicable

Assessing the Feasibility of Combining Dihydroartemisinin Piperaquine and Primaquine for Malaria Mass Drug Administration in High Endemic Communities in the Eastern Region of Ghana

NCT07389057
completedphase_2

KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)

NCT01626664
completedphase_1

Everolimus in Combination With DHAP in Patients With Relapsed or Refractory Hodgkin Lymphoma

NCT01453504
unknownphase_1

Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients

NCT02280993
completedphase_2

A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

NCT01453205
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT07389057Not Applicable

Assessing the Feasibility of Combining Dihydroartemisinin Piperaquine and Primaquine for Malaria Mass Drug Administration in High Endemic Communities in the Eastern Region of Ghana

Recruiting
NCT01626664Phase 2

KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)

Completed
NCT01453504Phase 1

Everolimus in Combination With DHAP in Patients With Relapsed or Refractory Hodgkin Lymphoma

Completed
NCT02280993Phase 1

Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients

Unknown
NCT01453205Phase 2

A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Completed
NCT00003143Phase 2

Combination Chemotherapy With or Without Amifostine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Disease Undergoing Stem Cell Transplantation

Completed
NCT00384553Phase 1

Risk Adapted Therapy Optimization for Patients With Relapsed or Refractory Aggressive Non-Hodgkin-Lymphoma

Unknown

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7